Avoidance of Drug Supply Unblinding Risks

(Durham, N.C. - October 30, 2012) – Stefan Dürr, Cenduit LLC associate director of project management and an expert in interactive response technology (IRT), will discuss how to avoid the risks of patient or material unblinding when defining drug supply specifications of IRT systems at the 2nd Annual Interactive Response Technologies for Clinical Trials Conference. The conference, which is sponsored by Cenduit, will take place November 8-9 in Philadelphia. 

Cenduit, an IRT provider for clinical trials serving more than 16,000 sites in more than 100 countries, offers IRT solutions that deliver optimized clinical supply chain management and facilitate precise control over patient randomization and drug administration to enable more efficient, compliant trials. The company's IRT-driven services include patient randomization, drug supply management, drug allocation, drug accountability, custom reporting and eClinical integration.

According to Dürr, IRT systems are used to ensure the integrity of blinded clinical trials. He will discuss several factors that must be considered as part of a well-designed drug supply strategy in an IRT system. These include creating appropriate material lists, examining resupply calculation options, defining the selection method for assigning the drug to shipments and patients, and managing drugs from different packaging campaigns.

"Without a well-planned drug supply strategy, the risk of partial or full unblinding events increases," said Dürr.

Dürr will be available for questions at the Cenduit booth.